Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission.
Jeffrey W. Church
Sr. Vice President – Corporate
Strategy and Investor Relations
email@example.com Celsion CorporationCondensed Statements of Operations
(in thousands except per share amounts)Year ended December 31,20122011Licensing revenue$
2,000Operating expenses: Research and development15,77019,864General and administrative 6,3735,155 Total operating expenses 22,14325,019
Loss from operations (22,143)(23,019)Other income (expense): (Loss) gain from valuation of common stock warrant liability(4,118)82Interest, dividends and other income (expense), net(307)(286)Total other income (expense), net(4,425)(204)
|SOURCE Celsion Corporation|
Copyright©2012 PR Newswire.
All rights reserved